LARIAM® Mefloquine 250 mg Tablets Shortage Notification

Pro Pharmaceuticals Group wishes to inform you that the Australian registered product LARIAM® mefloquine 250 mg (as hydrochloride) tablets blister pack (AUST R: 43321) is currently in shortage, as listed on the TGA Medicines Shortage Database.

Current Shortage Status

LARIAM mefloquine 250 mg tablets (AUST R: 43321)

• Availability: Limited availability

• Expected supply: 20 March 2026

• Management action: The sponsor is closely controlling supply and working to expedite the next shipment.

  
  

To ensure continuity of patient care, the Therapeutic Goods Administration (TGA) has granted approval under Section 19A of the Therapeutic Goods Act 1989 for the importation and supply of the following alternative product:

Alternative Product Information

Mefloquine Hydrochloride Tablets 250 mg

• Pack size: 8 tablets

• Manufacturer: AA Pharma Inc., Canada

  
  

This product is registered and marketed in Canada and is approved for temporary importation and supply in Australia until 30 April 2026.

Approved Indications

In adults and children over 45 kg bodyweight:

• Treatment of acute malaria due to Plasmodium falciparum resistant to conventional antimalarial drugs.

• Chemoprophylaxis of malaria in travellers to regions with documented chloroquine-resistant P. falciparum.

• Alternative prophylaxis for travellers hypersensitive to sulphonamides and sulphones.

  
  

Key Details

• Same active ingredient, strength, and dose form as the Australian registered product (mefloquine hydrochloride 250 mg tablets).

• Registered and marketed in Canada.

• English and French labelled packaging.

• Tablets may be swallowed whole or crushed and suspended for administration where required.

• Supplied in packs of 8 tablets.

• TGA-approved Dear Healthcare Professional letter available.

  
  

Pro Pharmaceuticals Group has commenced supply to Australian healthcare institutions and can support ongoing requirements while the Australian registered product remains in shortage.

We encourage hospital pharmacies and clinical teams to circulate this information internally.

Contact Information

For orders and enquiries, please reach out to us at:

• Email: orders@propg.com.au

• Phone: 1300 077 674

• Website: www.propg.com.au

  
  
  
  
  
  

Understanding the Importance of Mefloquine

Mefloquine is a critical medication used in the treatment and prevention of malaria. This drug plays a vital role in ensuring patient safety and health, especially in regions where malaria is prevalent. The shortage of LARIAM® has raised concerns, but the approval of alternative products ensures that we can continue to provide necessary care.

The Role of Regulatory Bodies

Regulatory bodies like the TGA are essential in managing drug shortages. Their actions help maintain the integrity of the healthcare supply chain. By granting approvals under the Special Access Scheme and Section 19A pathways, they ensure that healthcare professionals have access to necessary medications even when standard supplies are disrupted.

Commitment to Patient Care

At Pro Pharmaceuticals Group, we prioritize patient care above all. Our commitment to sourcing reliable, GDP-compliant pharmaceuticals ensures that healthcare providers can maintain continuity of treatment. We understand the challenges faced by hospitals and clinics during shortages and strive to be a dependable partner in these times.

Building Trust-Based Partnerships

Our long-term partnerships with hospitals, pharmaceutical companies, and licensed global suppliers are built on trust and reliability. We are dedicated to supporting healthcare providers in their mission to deliver uninterrupted patient treatment. Our structured and traceable supply chains reflect our commitment to compliance and quality.

Conclusion

In conclusion, while the shortage of LARIAM® mefloquine 250 mg tablets poses challenges, we are here to support the healthcare community. With the approval of alternative products and our commitment to reliable supply, we aim to ensure that patient care remains uninterrupted. Please do not hesitate to contact us for any inquiries or orders.

---

We appreciate your understanding and cooperation during this period. Thank you for your continued dedication to patient care.